Fasturtec: Side Effects & Dosing

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Rasburicase

Indications/Uses

Treatment & prophylaxis of acute hyperuricaemia to prevent acute renal failure in patients w/ haematological malignancy w/ high tumour burden & at risk of rapid tumour lysis or shrinkage at chemotherapy initiation.

Dosage/Direction for Use

IV Recommended dose: 0.2 mg/kg daily as a once daily 30 min infusion. Treatment duration: May be up to 7 days.

Contraindications

Hypersensitivity to rasburicase or uricases. G6PD deficiency & other cellular metabolic disorders known to cause haemolytic anaemia.

MIMS Class

Disease-Modifying Anti-Rheumatic Drugs (DMARDs) / Supportive Care Therapy / Antidotes & Detoxifying Agents

ATC Classification

V03AF07 - rasburicase ; Belongs to the class of detoxifying agents used in antineoplastic treatment.

Regulatory Classification

POM

Presentation/Packing

Form

Fasturtec soln for infusion 1.5 mg/mL

Packing/Price

1's

Fasturtec

rasburicase

Manufacturer:

sanofi-aventis